Table 3.
Single dose PK of compounds 11b and 11e.
Entry no. | Administrationa | T1/2 (h) | Cmax (ng/mL) | AUC(0-t) (h*ng/mL) |
AUC(0-∞) (h*ng/mL) |
F (%) |
---|---|---|---|---|---|---|
11b | IV | 0.47 ± 0.09 | -b | 2281 ± 325 | 2284 ± 324 | – |
PO | 0.91 ± 0.09 | 1597 ± 135 | 2155 ± 168 | 2161 ± 171 | 47.25 ± 3.69 | |
11e | IV | 0.74 ± 0.04 | – | 3783 ± 389 | 3857 ± 388 | – |
PO | 0.76 ± 0.03 | 3342 ± 1243 | 5143 ± 303 | 5153 ± 306 | 67.98 ± 4.01 | |
nirmatrelvirc | IV | 0.42 ± 0.10 | – | 2240 ± 101 | 2241 ± 101 | – |
PO | 0.51 ± 0.10 | 1819 ± 695 | 1023 ± 195 | 1029 ± 202 | 22.85 ± 4.35 |
Single IV dose was 10 mg/kg and PO dose was 20 mg/kg.
Not tested.
Used as a positive control.